Moneycontrol PRO
Upcoming Webinar:Innovate Your Future at India Inc. on the Move on August 26 and 27, 2021 at 10am, with Rockwell Automation
you are here: HomeNewsBusinessIPO

Tatva Chintan IPO: Why it attracted the second-highest subscription level among issues in 2021

Most companies are capitalising on suitable market conditions to raise equity capital at premium valuations. Tatva Chintan was no exception and investors bid for 180 times the shares that the company offered.

July 21, 2021 / 11:35 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Of the 28 initial public offerings in India in 2021, Tatva Chintan Pharma Chem’s was subscribed 180 times, the second-highest level, behind MTAR Technologies, which was subscribed 200 times.

Here’s why the Tatva Chintan IPO was so attractive:

IPO mania

Popular IPOs are often oversubscribed because traders and investors want to make listing gains. The premium of Tatva Chintan shares in the grey market was a hefty Rs 770 on July 20, the last day of the IPO, an indicator of why there was such an overwhelming response from investors.

Each share was offered in a price band of Rs 1,073 to Rs 1,083, with a minimum order quantity of 13 shares.

Close

Superior business model

Tatva Chintan is the only commercial manufacturer of structure-directing agents for zeolites in India. It is also the second-largest such company globally, according to F&S Report.

Zeolites have varied applications, including as catalysts and adsorbents. When combined with metals such as copper and iron, they are active for selective catalytic reduction, a way of emission control in automotive applications.

The company is one of the leading global producers of an entire range of phase transfer catalysts.

It has strong customer relationships with companies such as Merck, Bayer AG, Asian Paints, Ipox Chemicals KFT, Laurus Labs, Tosoh Asia, SRF and Navin Fluorine.

The company’s products have applications in green chemistry, which is relevant given the growing focus on sustainable technologies and solutions.

Healthy financials

Tatva Chintan’s revenue, earnings before interest, tax, depreciation and amortisation, and profit after tax increased at a compounded annual growth rate of about 21 percent, 39 percent, and 60 percent, respectively over FY19-21, with a 499 bps margin expansion. Return ratios seem healthy, with FY21 return on equity and return on capital employed at 31 percent and 27 percent, respectively, providing confidence to investors.

To Know All IPO Related News, Click Here

Our View

Given the wide application of its products, Tatva Chintan serves customers across various industries and geographies, providing diversification benefits. A high-quality product portfolio, strong R&D capabilities, strategically located manufacturing facilities and focus on green chemistry processes bode well for the company. A stable financial performance and better growth opportunities provide visibility for the long term. Considering all these factors, we rated the IPO ‘subscribe’ for the long term.

Image22072021

Disclaimer: The views and investment tips expressed by investment expert on Moneycontrol.com are his own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Nikhil Shetty is the Senior Research Analyst at BP Wealth. He has over 8 years of experience in the field of Equity Advisory, research and has been associated with BP Wealth since 2015.
first published: Jul 21, 2021 11:35 am

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark